iMeds.se

Ziprasidon Pfizer

Information för alternativet: Ziprasidon Pfizer 40 Mg Kapsel, Hård, Ziprasidon Pfizer 20 Mg Kapsel, Hård, Ziprasidon Pfizer 60 Mg Kapsel, Hård, Ziprasidon Pfizer 80 Mg Kapsel, Hård, visa andra alternativ



PACKAGE LEAFLET


Package leaflet: Information for the user


Ziprasidon Pfizer

20 mg, 40 mg, 60 mg, 80 mg capsules, hard


ziprasidone


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you


What is in this leaflet:

What Ziprasidon Pfizer are and what they are used for

What you need to know before you use Ziprasidon Pfizer

How to take Ziprasidon Pfizer

Possible side effects

How to store Ziprasidon Pfizer

Contents of the pack and other information


1. What Ziprasidon Pfizer are and what are they used for


Ziprasidon Pfizer belong to a group of medicines called antipsychotics.


Ziprasidon Pfizer are used for the treatment of schizophrenia in adults - a mental disorder characterised by the following symptoms: to hear, see and feel things that do not exist, to believe in something not true, to feel unusual suspicions, to be absent and have difficulty in establishing social relationships, nervousness, depression or anxiety.


Ziprasidon Pfizer are also used for the treatment of manic or mixed episodes of moderate severity in bipolar disorder in adults and children and adolescents aged 10-17 years - a mental disorder characterised by alternate stages of euphoric (mania) or depressed mood states. During mania episodes, the most characteristic symptoms are: elated behaviour, exaggerated self-esteem, increase in energy, decreased need for sleeping, lack of concentration or hyperactivity and repeated high risk-taking behaviour.


2. What you need to know before you use Ziprasidon Pfizer


Do not take Ziprasidon Pfizer


Also refer to the section “Other medicines and Ziprasidon Pfizer” below.


Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Ziprasidon Pfizer


Contact your doctor immediately if you experience any of the following:

Severe skin reactions such as rash with blisters which could include ulcers in the mouth, skin shedding, fever and target-like spots on the skin that could be symptoms of Stevens-Johnson syndrome. These skin reactions could potentially be life-threatening.


Tell your doctor that you are taking Ziprasidon Pfizer before you have a laboratory test (such as blood, urine, liver function, heart rate etc) because it may alter the results of the test.


Other medicines and Ziprasidon Pfizer

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.


Do not take Ziprasidon Pfizer if you take medicines for heart rhythm problems or medicines that may affect the heart’s rhythm, such as:

Class IA and III antiarrhythmics, arsenic trioxide, halofantrine, levomethadyl acetate, mesoridazine, thioridazine, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, dolasetron mesilate, mefloquine, sertindole or cisapride. These medicines affect the heart rhythm by prolonging the QT interval. If you have any further questions about this you should speak to your doctor.


Please tell your doctor or pharmacist if you are taking or have recently taken medicines for the treatment of:


Also refer to the section “Do not take Ziprasidon Pfizer” above.


Ziprasidon Pfizer capsules with food and drink

Ziprasidon Pfizer capsules MUST BE TAKEN DURING A MAIN MEAL.

You should not drink alcohol during treatment with Ziprasidon Pfizer, as this may increase the risk of side effects.


Pregnancy and breast-feeding


Pregnancy
You should not take
Ziprasidon Pfizerduring pregnancy unless you are told otherwise by your doctor because there is a risk that this medicine may harm your baby. Always use effective contraception. Tell your doctor immediately if you become pregnant or are planning to become pregnant whilst taking Ziprasidon Pfizer.


The following symptoms may occur in newborn babies, of mothers that have used Ziprasidon Pfizer in the last trimester (last three months of their pregnancy):shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.


Breast-feeding
Do not breast-feed if you are taking
Ziprasidon Pfizer. This is because small amounts may pass into the mother’s milk. If you are planning to breast-feed, talk to your doctor before taking this medicine.


Driving and using machines


Taking Ziprasidon Pfizermay make you feel drowsy. If you experience this symptom, you should not drive or use tools or machinery until the drowsiness disappears.


Ziprasidon Pfizer Capsules contain lactose

Ziprasidon Pfizer capsules contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Ziprasidon Pfizer capsules.


3. How to use Ziprasidon Pfizer


Always use this medicineexactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.


The capsules should be swallowed whole, not chewed and must be taken with meals. It is important not to chew the capsules as it may affect the extent to which the medicine is absorbed by the gut.


Ziprasidon Pfizer capsules should be taken twice daily, one capsule in the morning during a full ‘breakfast’ and one in the evening during the ‘evening meal’ (see the blister pack). You should take this medicine at the same time every day.


Adults

The recommended dose is 40-80 mg twice daily to be taken with meals.


In long-term treatments, your doctor may adjust the dose. You should not exceed the maximum dose of 160 mg per day.


Children and adolescents with bipolar mania

The usual starting dose is 20 mg to be taken with a meal, after which your doctor will advise on optimal doses for you. You should not exceed the maximum dose of 80 mg per day in children weighing 45 kg or less, or 160 mg per day in children weighing more than 45 kg.


The safety and efficacy of Ziprasidon Pfizer in the treatment of schizophrenia in children and adolescents has not been established.


Elderly (over 65 years old)

If you are elderly, your doctor will decide the suitable dose for you. Doses in those over 65 are sometimes lower than those used in younger people. Your doctor will advise you what the right dose is for you.


Patients with liver problems

If you have liver problems you may need to take a lower dose of Ziprasidon Pfizer. Your doctor will work out the correct dose for you.



If you take more Ziprasidon Pfizerthan you should

Contact your doctor or go to the nearest hospital casualty department immediately. Take your box of Ziprasidon Pfizer capsules with you.


If you have taken too many Ziprasidon Pfizer, you may experience drowsiness, shaking, fits and involuntary movements of the head and neck.


If you forget to take Ziprasidon Pfizer

It is important you take Ziprasidon Pfizerregularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just take your next dose. Do not take a double dose to make up for a forgotten dose.


If you stop taking Ziprasidon Pfizer

Your doctor will tell you how long to take Ziprasidon Pfizer for. You should not stop using Ziprasidon Pfizer, unless your doctor has told you to.


It is important to continue with your medication, even if you feel better. If you stop the treatment too early, the symptoms may return.


If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


4. Possible side effects


Like all medicines, this medicinecan cause side effects, although not everybody gets them. However, most side effects are transient. It may often be difficult to distinguish the symptoms of your disease from those of side effects.


STOP taking Ziprasidon Pfizerand contact your doctor immediately if you experience any of the following serious side effects:

Common side effects (may affect up to 1 in 10 people):

Involuntary/unusual movements, especially in your face or tongue.


Uncommon side effects (may affect up to 1 in 100 people):

Fast or irregular heartbeat, dizziness on standing up which may indicate abnormal functioning of the heart. These could be symptoms of a condition known as postural hypotension.


Rare side effects (may affect up to 1 in 1,000 people):


You may experience any of the following side effects listed below. These potential side effects generally are mild to moderate and may resolve with time. However, if the side effect is severe or persistent, you should contact your doctor.


Very Common side effects (may affect more than 1 in 10 people):


Common side effects (may affect up to 1 in 10 people):


Uncommon side effects (may affect up to 1 in 100 people):

High levels of prolactin in the blood


Rare side effects (may affect up to 1 in 1,000 people):


Not known (frequency cannot be estimated from the available data):

In elderly people with dementia, a small increase in the number of deaths has been reported for patients taking antipsychotics compared with those not receiving antipsychotics.

Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.


Reporting of side effects

If you get any side effects talk toyour doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


5. How to store Ziprasidon Pfizer Capsules


Keep this medicine out of the sight and reach of children.


Do not use this medicine after the expiry date, which is stated on the carton after (EXP:). The expiry date refers to the last day of that month.


Do not store above 30ºC.


Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information


What Ziprasidon Pfizercapsules contain

The active substance is ziprasidone. Each capsule contains 20 mg, 40 mg, 60 mg or 80 mg of ziprasidone as ziprasidone hydrochloride monohydrate.


The other ingredients are: lactose monohydrate, pregelatinised maize starch, magnesium stearate, gelatin, titanium dioxide (E171), sodium laurilsulfate (sodium dodecylsulphate) and indigotin (E132) for capsules containing blue (20, 40 and 80 mg), shellac, propylene glycol, potassium hydroxide and black iron oxide (E172).


What Ziprasidon Pfizercapsules look like and contents of the pack

Ziprasidon Pfizer capsules are hard gelatin capsules.

Ziprasidon Pfizer capsules 20 mg are blue/white and marked Pfizer” and ZDX 20.

Ziprasidon Pfizer capsules 40 mg are blue and marked Pfizer” and ZDX 40.

Ziprasidon Pfizer capsules 60 mg are white and marked Pfizer” and ZDX 60.

Ziprasidon Pfizer capsules 80 mg are blue/white and marked Pfizer” and ZDX 80.


Pack sizes:

Aluminium PVC/PVA blisters containing 14, 20, 28, 30, 50, 56, 60, 98 or 100 capsules.


Plastic bottle (HDPE) with drying agent and child-proof screw cap containing 100 capsules.

A heat induction seal may be used as a closure, in which case no drying agent is included


Not all pack sizes may be marketed.


Marketing Authorisation Holder

[To be completed nationally]


Manufacturer:

R-Pharm Germany GmbH, Heinrich-Mack-Str. 35, 89257 Illertissen, Germany


This medicinal product is authorised in the Member States of the EEA under the following names:


Ziprasidon Pfizer – Austria, Denmark, Finland, Iceland, Norway, Sweden

Ziprasidone Pfizer – Ireland, Italy

Ziprasidon Pfizer 20 mg, 40 mg, 60 mg, 80 mg Hartkapseln Germany

Ziprasidona Parke-Davis – Portugal

Ziprasidona Pharmacia - Spain

Embreval - Greece


This leaflet was last revised in:

2016-10-06


1